首页 | 本学科首页   官方微博 | 高级检索  
     

盘龙七片治疗强直性脊柱炎的临床研究
引用本文:赵福涛,赵浩. 盘龙七片治疗强直性脊柱炎的临床研究[J]. 中国中西医结合杂志, 2007, 27(6): 540-542
作者姓名:赵福涛  赵浩
作者单位:上海交通大学医学院附属第三人民医院风湿免疫科,上海,201900
摘    要:目的对盘龙七片治疗强直性脊柱炎(ankylosing spondylitis,AS)的疗效进行为期6个月的临床观察,以评价其治疗AS的疗效和安全性。方法门诊和住院治疗的AS患者104例采用随机数字表法分为治疗组和对照组各52例。对照组采用非甾体类抗炎药(NSAID)和柳氮磺吡啶(sulfasalazine,SSZ)治疗,治疗组在此基础上加用盘龙七片(panlongqipian,PLQ)治疗,观察临床症状、BathAS活动指数(BASDAI)、BathAS功能指数(BASFI)、ESR和CRP等实验室检查及不良反应。分别于治疗3个月复诊和治疗6个月随访。结果两组治疗第3、6个月与治疗前比较,腰骶痛明显减轻(P〈0.05),腰背晨僵时间显著缩短(P〈0.05),BASDAI和BASFI明显降低(P〈0.05),ESR和CRP亦显著下降(P〈0.05);治疗组第3、6个月腰背晨僵时间、BASDAI、BASFI、ESR和CRP与对照组比较,差异均有显著性(P〈0.05)。不良反应以胃肠道反应为主,两组比较差异无显著性(P〉0.05)。结论PLQ治疗AS疗效显著,且不良反应轻微,可用于AS的辅助治疗。

关 键 词:强直性脊柱炎  盘龙七片  柳氮磺吡啶  疗效  安全性
收稿时间:2006-12-04
修稿时间:2007-03-15

Clinical Study on Treatment of Patients with Ankylosing Spondylitis by Panlongqi Tablet
ZHAO Fu-tao and ZHAO Hao. Clinical Study on Treatment of Patients with Ankylosing Spondylitis by Panlongqi Tablet[J]. Chinese journal of integrated traditional and Western medicine, 2007, 27(6): 540-542
Authors:ZHAO Fu-tao and ZHAO Hao
Abstract:Objective A 6-month observation on curative effect of Panlongqi Tablet (PLQ) in treating patients with ankylosing spondylitis (AS) was conducted for evaluating its efficacy and safety. MethodsOne hundred and four inpatients and outpatients with AS were randomly assigned to two groups by using random number table, 52 in each group. All patients were treated non-steroid anti-inflammatory drug (NSAID) and sulfasalazine (SSZ), and those in the treated group were given with PLQ additionally. The change of symptoms and signs were observed, and some laboratory indexes as Bath AS disease activity index (BASDAI), Bath AS functional index (BASFI), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), as well as adverse reaction were observed as well. The revisit and follow-up study were carried out at the 3 months and 6 months respectively. ResultsThe lumbosacral pain was significantly alleviated, the time for lumbodorsal morning stiffness was shortened, the levels of BASDAI, BASFI, ESR and CRP were significantly lowered after treatment for 3 months or 6months (P<0.05), and these improvements were more significant in the treated group as compared with those in the control group (P<0.05). The main adverse reactions was dominantly the gastrointestinal symptoms, which showed insignificant difference between the two groups (P>0.05 ). ConclusionPLQ is an effective traditional medicine for AS with mild adverse reaction, it can be used as an adjuvant therapy.
Keywords:spondylitis  ankylosing  Panlongqi Tablet  sulfasalazine
本文献已被 CNKI 维普 万方数据 等数据库收录!
点击此处可从《中国中西医结合杂志》浏览原始摘要信息
点击此处可从《中国中西医结合杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号